Dolutegravir
DrugDolutegravir will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
Other names: Dolutegravir Sodium, DTG
NCT Number: NCT04862975
The purpose of this study is to characterize the pharmacokinetics (PK) of understudied drugs administered to lactating women, receiving antiretroviral drugs per SOC as prescribed by their healthcare provider, and their co-enrolled infants ≤180 days of age who receive maternal breastmilk.
Looking for future studies?
Notify Me18 year and older
Female
Observational
Botswana-UPenn Partnership, Botswana, Gaborone, South Africa
Prospective, single-site, open label, PK and safety study. Co-enrollment of lactating women ≥18 years of age receiving drugs of interest (DOIs) per standard of care (SOC), as prescribed by their healthcare providers, and their infants who receive maternal breastmilk ≤180 days postpartum.
To understand drug transfer into breastmilk and determine subsequent infant exposure, biological samples will be collected from lactating women (blood and breastmilk) and infants (blood). The opportunistic design of this study will allow for a minimal risk study, an expanded enrollment net, evaluation of antiretroviral drugs, and capitalization of procedures performed per SOC to maximize study efficiency and data collection and minimize potential risk to participants. The data collected through this initiative will provide valuable PK, dosing, and safety information for drugs in this vulnerable population in order to inform public health.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Mothers/Infants:
Exclusion criteria
Mothers/Infants:
Dolutegravir will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
Other names: Dolutegravir Sodium, DTG
Lamivudine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
Other names: 3TC
Emtricitabine will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
Other names: FTC
Tenofovir Disoproxil Fumarate will be administered in accordance with local SOC as prescribed by the lactating woman's healthcare provider. Not prescribed for this study.
Other names: Tenofovir DF, TDF
Time frame: Baseline
Drug concentration of a DOI in maternal plasma
Time frame: Baseline
Drug concentration of a DOI in maternal breastmilk
Time frame: Baseline
Drug concentration of a DOI in infant plasma
Time frame: Baseline
The drug exposure of selected DOIs will be evaluated using milk/plasma ratio
Time frame: Baseline
The drug exposure of selected DOIs will be evaluated using the estimated daily infant dose
Time frame: Baseline
The drug exposure of selected DOIs will be evaluated using relative infant dose
Time frame: Baseline
The drug exposure of selected DOIs will be evaluated using infant/maternal exposure ratio
Time frame: Baseline
Clearance (CL) or apparent clearance (CL/F)
Time frame: Baseline
Volume of distribution (V) or apparent volume of distribution (V/F)
Time frame: Baseline
Elimination Half-life (t1/2)
Time frame: Baseline
Absorption rate constant (ka)
Time frame: Baseline
Area under the curve (AUC)
Time frame: Baseline
Elimination rate constant (kel)
Time frame: Baseline
Maximum concentration (CMAX)
Time frame: Baseline
Time to reach maximum concentration (TMAX)
Time frame: Baseline
Correlation of drug concentration of each DOI in maternal breastmilk with maternal BMI
Time frame: Baseline
Correlation of drug concentration of each DOI in maternal plasma with maternal BMI
Time frame: Baseline
Correlation of drug concentration of each DOI in infant plasma with maternal BMI
Time frame: Baseline
Correlation of milk/plasma ratio of each DOI with maternal BMI
Time frame: Baseline
Correlation of estimated daily infant dose of each DOI with maternal BMI
Time frame: Baseline
Correlation of relative infant dose of each DOI with maternal BMI
Time frame: Baseline
Correlation of infant/maternal exposure ratio for each DOI with maternal BMI
Time frame: Baseline
Will be collected from the medical record at the time of sample collection
Duke University
Other
Acronym: BMS02
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03511118
Breastfed Infants of Mothers on Select DOI, Lactating Women on Select DOI
La Jolla, California, United States
View Trial DetailsNCT03048422
Blood-Borne Infections, Communicable Diseases
Jacksonville, Florida, United States
View Trial DetailsNCT05388474
Blood-Borne Infections, Communicable Diseases
Los Angeles, California, United States
View Trial DetailsNCT03284710
Blood-Borne Infections, Communicable Diseases
Maputo, Mozambique
View Trial Details